|
| Press Releases |
|
 |
|
| Friday, March 13, 2026 |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo |
| more info >> |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo |
| On 12 March 2026, China Medical System Holdings Limited is pleased to announce that its subsidiary, Dermavon Holdings Limited has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix(R)) (the "Product", marketed as Opzelura(R) in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. more info >> |
|
| Thursday, March 5, 2026 |
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity |
| more info >> |
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection ("CMS-D008") received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration ("NMPA") on 4 March 2026. more info >> |
|
| Tuesday, February 24, 2026 |
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China |
| more info >> |
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China |
| CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China more info >> |
|
| Friday, January 30, 2026 |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China |
| CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China more info >> |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China |
| CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China more info >> |
|
| Wednesday, July 16, 2025 |
|
|
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today |
| more info >> |
|
|
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today |
| On the morning of 15 July 2025, China Medical System Holdings Limited ("CMS" or the "Group") rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Zylo Ecosystem Announces the Launch of the ZYLO Token to Expand Its Digital Ecosystem
Mar 17, 2026 08:00 HKT/SGT
|
|
|
FinHarbor Introduces Neobank Platform Designed to Go Live in Under 30 Days
Mar 16, 2026 20:30: JST
|
|
|
FinHarbor Introduces Neobank Platform Designed to Go Live in Under 30 Days
Mar 16, 2026 20:30 HKT/SGT
|
|
|
THERMAL-XR(R) Sales in the United States to Commence After GMG Receives U.S. EPA Approval
Mar 16, 2026 19:59 HKT/SGT
|
|
|
Hitachi Energy Japan Recognized as a 2026 Health & Productivity Management Outstanding Organization (Large Enterprise Category)
Mar 16, 2026 16:20 JST
|
|
|
Bonus Savings Account: What It Is and How It Helps You Earn More Interest
Mar 16, 2026 15:10 HKT/SGT
|
|
|
China Lilang Announces 2025 Annual Results
Mar 16, 2026 13:15 HKT/SGT
|
|
|
中國利郎公佈二零二五年全年業績
Mar 16, 2026 13:15 HKT/SGT
|
|
|
中国利郎公布二零二五年全年业绩
Mar 16, 2026 13:15 HKT/SGT
|
|
|
Fujitsu Japan and Teikyo University Hospital launch joint proof of concept to build mechanism for data analysis and referred-patient management
Mar 16, 2026 12:55 JST
|
|
|
Accelerated Technology Commercialization Drives High-Growth Performance, Qunabox Group Leads the AI Interactive Marketing Track
Mar 16, 2026 10:55 HKT/SGT
|
|
|
富士通Japanと帝京大学医学部附属病院、紹介患者の受け入れ増加を目指し、データ分析および紹介患者管理の仕組みの構築に関する実証実験を開始
Mar 16, 2026 10:20: JST
|
|
|
富衛集團2025年全年業績創新高 實現盈利增長及資本與現金流創造能力提升
Mar 16, 2026 09:25 HKT/SGT
|
|
|
FWD Group delivers record full year 2025 results with profitable growth, improved capital and cash flow generation
Mar 16, 2026 10:25 JST
|
|
|
Exito Media Concepts Announces the 30th Edition of the Cyber Security Summit Philippines 2026
Mar 16, 2026 08:26 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
